Celecoxib decreases prostaglandin E2 concentrations in nipple aspirate fluid from high risk postmenopausal women and women with breast cancer

[1]  Randall Harris,et al.  Reduction in the risk of human breast cancer by selective cyclooxygenase-2 (COX-2) inhibitors , 2006, BMC Cancer.

[2]  E. Sauter,et al.  Lack of effect of celecoxib on prostaglandin E2 concentrations in nipple aspirate fluid from women at increased risk of breast cancer. , 2004, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[3]  I. Russo,et al.  The cyclooxygenase-2 inhibitor, celecoxib, prevents the development of mammary tumors in Her-2/neu mice. , 2003, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[4]  B. Whittle.  Gastrointestinal effects of nonsteroidal anti‐inflammatory drugs , 2003, Fundamental & clinical pharmacology.

[5]  L. Zhong,et al.  Plasma PGE-2 levels and altered cytokine profiles in adherent peripheral blood mononuclear cells in non-small cell lung cancer (NSCLC) , 2002, Molecular Cancer.

[6]  K. Seibert,et al.  Chemotherapeutic evaluation of Celecoxib, a cyclooxygenase-2 inhibitor, in a rat mammary tumor model. , 2000, Oncology reports.

[7]  B. Levin,et al.  The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. , 2000, The New England journal of medicine.

[8]  K. Seibert,et al.  Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor. , 2000, Cancer research.

[9]  K. Seibert,et al.  Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. , 2000, Cancer research.

[10]  B. Fisher.  Highlights from recent National Surgical Adjuvant Breast and Bowel Project studies in the treatment and prevention of breast cancer , 1999, CA: a cancer journal for clinicians.

[11]  M. Taketo.  Cyclooxygenase-2 inhibitors in tumorigenesis (Part II). , 1998, Journal of the National Cancer Institute.

[12]  E. Diamandis,et al.  Prostate-specific antigen levels in nipple aspirate fluid correlate with breast cancer risk. , 1996, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[13]  E. Meagher.  Balancing Gastroprotection and Cardioprotection with Selective Cyclo-Oxygenase-2 Inhibitors , 2003, Drug safety.

[14]  P. Engstrom,et al.  Nipple aspirate fluid: a promising non-invasive method to identify cellular markers of breast cancer risk. , 1997, British Journal of Cancer.